Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis

ConclusionsThe L-AMB/isavuconazonium sulphate combination demonstrated greater activity versus monotherapy in immunosuppressed mice infected with either of the two most common causes of mucormycosis. These studies warrant further investigation of L-AMB/isavuconazonium sulphate combination therapy as an optimal therapy of human mucormycosis.
Source: Journal of Antimicrobial Chemotherapy - Category: Microbiology Source Type: research